1

A. Impacts already occurring
   - Targeted therapy
   - Implants
   - Collaborative research and new collab btw large and SME
   - Open space to grow new business in SME, + academia
   - Conservatism of the customer groups,
   - Opportunity to rescue drugs that have been abandoned
   - For NT to interact with parts of the treatment paths not currently
   - Growth in academic fields and technology entities and IP
   - Nanotechnology diversity and the valley of death
     - Industry is not ready to pick up

B. Next 5 years
   - Growth of already occurring
   - Expect something in trials will be on market (therapeutics, Dx, lab on chip, etc)
   - More funding and acceptance by pharma
   - Standardization of metrics and therefore accelerated regulatory recognition and approval
   - Personalized medicine and ability to etter identifiysusceptile patients

2 - How do you expect metrics for economic impacts to shift as NT in this sector evolves

- Indirect impacts: improved patient outocmes
  - Quality of life
  - Productivity
  - Lowered HC costs
  - Redistribution of values
  - Move from econ-oriented to socially-oriented
    - Maintenance of health years and productivity
  - Multi-dimensional
  - Manufacturability
- Impact on developing economies- centralize healthcare infrastructure (increased efficiency and distribution)

3

- More qualitative methodologies
  - Departure from counting

4 – unique challenges

- Dealing with humans
- Population effects of improved cancer survival
- Regulatory approval
- Horizontal character of applications